An independent LDT provider
Reports & Presentations
Share capital development
Board of Directors
Articles of association
Rights issue 2023
Listing transfer (2018)
Rights Issue (2016)
Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:
April 28, 2022
Immunovia Interim Report January-March 2022 Presentation
March 9, 2022
Cowen’s 42nd Annual Health Care Conference
February 17, 2022
Immunovia Full Year Report 2021 Presentation
January 4, 2022
New Year Letter from Chairman Carl Borrebaeck to all shareholders
December 23, 2021
Year-end greeting from Patrik Dahlen, CEO Immunovia, to all...
December 2, 2021
Patrik Dahlen, CEO of Immunovia, presents the company at Erik Penser...
November 16, 2021
Jefferies London Healthcare Conference
October 12, 2021
Immunovia CEO Patrik Dahlen presents the company at Vator Securities...
August 26, 2021
Immunovias CEO Patrik Dahlen presents the company at Erik Penser...
June 10, 2021
Immunovia Key Opinion Leader Event on the Clinical Use of IMMray™...
March 30, 2021
Immunovia reports historical breakthrough in early detection of...
December 17, 2020
Immunovia’s IMMray™ PanCan-d Webinar Series